SVB Leerink reiterated coverage on Adaptimmune Therapeutics with a new price target
$ADAP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
SVB Leerink reiterated coverage of Adaptimmune Therapeutics with a rating of Market Perform and set a new price target of $5.00 from $6.00 previously